Latest Convertible Notes News

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

XPON Technologies has posted a strong H1 FY26 turnaround with a 58% revenue increase and a return to net profitability, driven by strategic acquisitions and operational improvements.

Global Masters Fund Limited reported a half-year net loss despite a modest increase in operating revenue, impacted by currency fluctuations and portfolio underperformance. No dividend was declared as the fund focuses on long-term capital growth.

Tartana Minerals is advancing its strategic metals portfolio in Far North Queensland with a robust 2026 drilling program and ongoing copper sulphate production, aiming to unlock significant resource potential across silver, gold, and copper assets.

NAOS Emerging Opportunities Company Limited has reported a robust half-year profit increase of 103%, alongside a fully franked interim dividend of 2.10 cents per share, reflecting strong portfolio performance and market confidence.

Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.

5E Advanced Materials reports Q2 FY2026 results with increased mineral resources and key shipments, while navigating ongoing funding uncertainties.

Jayride Group Limited reports a narrower quarterly loss amid revenue challenges, secures $200,000 through convertible notes, and inks a new SaaS agreement with Thailand’s Drivemate to expand its mobility platform.

Osteopore Limited has drawn down the second tranche of its redeemable convertible notes, raising A$500,000 as part of a broader A$20 million funding agreement with Advance Opportunities Fund. The funds are earmarked to support ongoing operations and future growth initiatives.

New Hope Corporation reported a 4.8% rise in coal production and an 8.2% increase in sales for the January quarter, maintaining steady earnings and reducing capital expenditure guidance amid improving logistics and operational resilience.

Wellnex Life Limited is exploring acquisition interest and convertible note funding to accelerate Pain Away's expansion and strengthen its financial footing, signaling a pivotal phase in its turnaround journey.

Eden Innovations has appointed Dr Allan Godsk Larsen as Managing Director to spearhead its global growth, leveraging his deep expertise in carbon nanotube technology amid strong commercial momentum and significant debt reduction.